# A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease

> **NCT07048197** · PHASE1,PHASE2 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 27 (estimated)

## Conditions studied

- Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)

## Interventions

- **BIOLOGICAL:** Rapcabtagene autoleucel

## Key facts

- **NCT ID:** NCT07048197
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-20
- **Primary completion:** 2028-11-01
- **Final completion:** 2028-11-01
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07048197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07048197, "A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07048197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*